The relationships between neuroglial and neuronal changes in Alzheimer's disease, and the related controversies II: gliotherapies and multimodal therapy.

Since the original description of Alzheimer´s disease (AD), research into this condition has mainly focused on assessing the alterations to neurons associated with dementia, and those to the circuits in which they are involved. In most of the studies on human brains and in many models of AD, the glial cells accompanying these neurons undergo concomitant alterations that aggravate the course of neurodegeneration. As a result, these changes to neuroglial cells are now included in all the "pathogenic cascades" described in AD. Accordingly, astrogliosis and microgliosis, the main components of neuroinflammation, have been integrated into all the pathogenic theories of this disease, as discussed in this part of the two-part monograph that follows an accompanying article on gliopathogenesis and glioprotection. This initial reflection verified the implication of alterations to the neuroglia in AD, suggesting that these cells may also represent therapeutic targets to prevent neurodegeneration. In this second part of the monograph, we will analyze the possibilities of acting on glial cells to prevent or treat the neurodegeneration that is the hallmark of AD and other pathologies. Evidence of the potential of different pharmacological, non-pharmacological, cell and gene therapies (widely treated) to prevent or treat this disease is now forthcoming, in most cases as adjuncts to other therapies. A comprehensive AD multimodal therapy is proposed in which neuronal and neuroglial pharmacological treatments are jointly considered, as well as the use of new cell and gene therapies and non-pharmacological therapies that tend to slow down the progress of dementia.

The relationships between neuroglial alterations and neuronal changes in Alzheimer's disease, and the related controversies I: Gliopathogenesis and glioprotection.

Since Alois Alzheimer described the pathology of Alzheimer's disease in 1907, an increasing number of studies have attempted to discover its causes and possible ways to treat it. For decades, research has focused on neuronal degeneration and the disruption to the neural circuits that occurs during disease progression, undervaluing in some extent the alterations to glial cells even though these alterations were described in the very first studies of this disease. In recent years, it has been recognized that different families of neuroglia are not merely support cells for neurons but rather key and active elements in the physiology and pathology of the nervous system. Alterations to different types of neuroglia (especially astroglia and microglia but also mature oligodendroglia and oligodendroglial progenitors) have been identified in the initial neuropathological changes that lead to dementia, suggesting that they may represent therapeutic targets to prevent neurodegeneration. In this review, based on our own studies and on the relevant scientific literature, we argue that a careful and in-depth study of glial cells will be fundamental to understanding the origin and progression of Alzheimer's disease. In addition, we analyze the main issues regarding the neuroprotective and neurotoxic role of neuroglial changes, reactions and/or involutions in both humans with Alzheimer's disease and in experimental models of this condition.

Reflections on Cerebellar Neuropathology in Classical Scrapie.

In this review, the most important neuropathological changes found in the cerebella of sheep affected by classical natural scrapie are discussed. This disease is the oldest known of a group of unconventional "infections" caused by toxic prions of different origins. Scrapie is currently considered a "transmissible spongiform encephalopathy" (due to its neuropathological characteristics and its transmission), which is the paradigm of prion pathologies as well as many encephalopathies (prion-like) that present aberrant deposits of insoluble protein with neurotoxic effects due to errors in their catabolization ("misfolding protein diseases"). The study of this disease is, therefore, of great relevance. Our work data from the authors' previous publications as well as other research in the field. The four most important types of neuropathological changes are neuron abnormalities and loss, neurogliosis, tissue vacuolization (spongiosis) and pathological or abnormal prion protein (PrP) deposits/deposition. These findings were analyzed and compared to other neuropathologies. Various aspects related to the presentation and progression of the disease, the involution of different neuronal types, the neuroglial responses and the appearance of abnormal PrP deposits are discussed. The most important points of controversy in scrapie neuropathology are presented.

Reproducción y cerebro. I. Bases morfofuncionales del control cerebral: avances y dilemas / Reproduction and brain. I Morphofunctional basis of brain control: advances and therapeutical implications

Desde hace muchos años se considera que el control de la reproducción radica en el cerebro y que el hipotálamo es la región del SNC directamente implicada en esta función. Clásicamente se había descrito un eje hipotálamo-hipofisario-gonadal encargado de controlar la función reproductora. Los avances de los últimos años confirman este concepto, pero se está demostrando que existe una mayor dependencia del eje al estar íntimamente conectado con el resto del SNC, con otros ejes reguladores hipotalámicos (energía y metabolismo, medio líquido interno, control simpático y parasimpático, estrés, hormonas, etc) y con el resto del organismo. Se reciben, además, de manera directa o indirecta, informaciones nerviosas y moleculares del medio interno y de situaciones del medio externo con mayor amplitud y selectividad que lo anteriormente descrito. Las amplias interconexiones que cada vez se van poniendo más de manifiesto (entre los núcleos y neuronas no secretoras y secretoras del hipotálamo; entre éstas neuronas y las extrahipotalámicas; y entre los ejes funcionales descritos), hacen cada vez más difícil describir con exactitud la base morfofuncional de cada individuo de cada especie en cada situación (sexo, edad, estadio del ciclo reproductivo, condiciones externas y externas), máxime cuando existen enormes capacidades de adaptación de las células y los sistemas funcionales. Las neuronas descritas en los últimos años relacionadas con la reproducción son las neuronas secretoras de GnRH, GnIH y Kisspeptina (neuronas productoras de la hormona liberadora de gonadotropina, la hormona inhibidora de las neuronas GnRH y las neuronas reguladoras de GnRH mediante el péptido Kisspeptina), pero todavía se desconoce si existen otros péptidos reguladores de las gonadotropinas hipofisarias así como de otras neuronas (o péptidos) que producen factores controladores de estas neuronas. Sí se sabe que estas neuronas están formadas por subconjuntos que pueden secretar otras substancias y/o ser reguladas de diferente manera. La gran variabilidad de las conexiones sinápticas y la secreción de neuropéptidos parece indicar que es necesario conocer la ‘modalidad funcional’ específica (o cuadro éspecífico de una situación en un individuo de una especie) más que las células intervinientes en un proceso. La compleja interrelación de los subtipos morfofuncionales de las neuronas secretoras y no secretoras de los diferentes núcleos o áreas del hipotálamo relacionadas con la reproducción plantea dudas sobre la actuación terapéutica. Posibles tratamientos farmacológicos y no farmacológicos, estimulando ‘específicamente’ algunos tipos neuronales, pueden tener consecuencias adversas al desestimar conexiones colaterales a otros sistemas o desconocer la existencia de neuronas de un subtipo en otras ‘vía’ o ‘ejes’ funcionales del hipotálamo, con lo que se podrían inducir fenómenos secundarios de gran transcendencia (AU)

For many years, the control of reproduction has been considered a brin function, being the hypothalamus the CNS region directly involved. The main neurons described in recent years related to reproduction are the secretory neurons of GnRH, GnIH and Kisspeptine (gonadotropin-releasing hormone; the gonadotropin-inhibitory hormone and by the peptide Kisspeptine- GnRH regulatory neurons), but it is still unknown whether other pituitary gonadotropin regulatory peptides exist as well as other neurons (or peptides) that produce regulatory factors for these neurons. It is known that these neurons are formed by subsets that can secrete other substances and/or be regulated in different ways. The great variability of the synaptic connections and the secretion of neuropeptides seem to indicate that it is necessary to know the specific ’functional modality’ (or specific picture of a situation in an individual of a species) rather than the cells involved in a process. The complex interrelationship of the morphofunctional subtypes of secretory and non-secreting neurons of the different nuclei or areas of the hypothalamus related to reproduction raises doubts about the therapeutic performance. Possible pharmacological and non-pharmacological treatments, specifically stimulating some neuronal types, may have important side effects by disregarding collateral connections to other systems or by ignoring the existence of neurons of a subtype in other functional ‘axes’ of the hypothalamus (AU)

Defective Insulin Signalling, Mediated by Inflammation, Connects Obesity to Alzheimer Disease; Relevant Pharmacological Therapies and Preventive Dietary Interventions.

BACKGROUND: Recent evidence suggests that obesity, besides being a risk factor for cardiovascular events, also increases the risk of Alzheimer's disease. Insulin resistance is common in all cases of obesity and appears to be the linkage between both diseases. Obesity, often associated with excessive fat and sugar intake, represents a preclinical stage toward insulin resistance during which nutrition intervention is likely to have maximum effect. OBJECTIVE: In this way, healthy lifestyles lifetime to prevent obesity-related modifiable risk factors such as inflammation, oxidative stress and metabolic disorders could be simultaneously beneficial for preserving cognition and controlling the Alzheimer's disease. METHOD: This review relates extensive research literature on facts linking nutrients and dietary patterns to obesity and Alzheimer's disease. In addition briefly presents molecular mechanisms involved in obesity- induced insulin resistance and the contribution of peripheral inflammatory and defective insulin signalling pathways, as well as ectopic lipids accumulation to Alzheimer's development through brain inflammation, neuronal insulin resistance, and cognitive dysfunction seen in Alzheimer's disease. RESULTS: The work relates current and emerging pharmacological and non-pharmacological therapies for the management of obesity, insulin resistance and Alzheimer's considering them as disorders with common molecular features. CONCLUSION: The findings of this review validate the importance of some nutritional interventions as possible approach to prevent or delay simultaneously progression of Alzheimer's disease and obesity.

Obesidad: ¿un riesgo para la enfermedad de Alzheimer? I. Mecanismos moleculares comunes / Obesity: a risk for Alzheimer's disease? I. Common molecular mechanisms

La obesidad es un factor de riesgo reconocido para las enfermedades cardiovasculares y el principal responsable de la resistencia a la acción de la insulina, estado que precede al desarrollo de diabetes de tipo 2. En los últimos años, las investigaciones han demostrado que existen además mecanismos moleculares comunes entre la obesidad y la enfermedad de Alzheimer, siendo el vínculo patológico más probable un estado de resistencia a la insulina que es mediado por inflamación. Si la disfunción cerebral en el Alzheimer efectivamente comparte mecanismos subyacentes con la obesidad, ciertas moléculas de señalización intracelular podrían estar involucradas en ambas enfermedades. La identificación de estas moléculas y su consideración como dianas terapéuticas supondrían un gran avance en el conocimiento de los mecanismos de estas enfermedades, y una buena estrategia en el desarrollo de nuevas terapias para ambos trastornos. En este trabajo se revisan las últimas hipótesis que vinculan la obesidad con Alzheimer. Se describe la disfunción del tejido adiposo y su consecuente acumulación de grasa ectópica como origen de estados sistémicos de inflamación y de resistencia a la insulina, característicos de la obesidad. Asimismo, se destacan estos estados sistémicos patológicos periféricos como principales responsables de estados de neuroinflamación y de resistencia a la insulina en el cerebro que conllevarían al deterioro cognitivo y disfunción neuronal encontrados en la enfermedad de Alzheimer

Obesity is a recognized risk factor for cardiovascular diseases and the main responsible for the resistance to the action of insulin, a state that precedes the development of diabetes type 2. In the last years, researches have demonstrated that there are also common molecular mechanisms between obesity and Alzheimer's disease, to be the more likely pathological link a state of insulin resistance, which is mediated by inflammation. If the brain dysfunction in Alzheimer's effectively shares underlying mechanisms with obesity, certain intracellular signaling molecules might be involved in both diseases. Identification of these molecules and their consideration as therapeutic targets would represent a breakthrough in the understanding of the mechanisms of these diseases, and an excellent strategy in the development of new therapies for both pathologic conditions. In this work the last hypothesis linking obesity with Alzheimer's disease are reviewed. Adipose tissue dysfunction and consequent accumulation of ectopic fat as a cause of inflammation and insulin resistance systemic conditions obesity characteristics are described. It also highlights these peripheral systemic pathological states as primarily responsible for neuroinflammation and insulin resistance in the brain that would lead to the neuronal dysfunction and cognitive impairment found in Alzheimer's disease

Nuevos conceptos sobre la funcionalidad del sistema nervioso: la revolución de las células gliales. II. Las respuestas neurogliales claves en la patogenia y el tratamiento de las enfermedades del SN / New concepts on the functionality of the nervous system: the revolution of the glial cells. II. Glial responses keys in the pathogenesis and treatment of diseases of SN

Todos los miembros de las familias de la neuroglía tienen la capacidad de adoptar un estado reactivo ('gliosis' de manera general; 'astrogliosis', 'oligodendrogliosis' y 'microgliosis', en su forma más específica) ante situaciones en que se modifica de manera importante la homeostasis del tejido nervioso y/o la dinámica funcional normal de las neuronas y sus células gliales acompañantes (traumas, intoxicaciones, infecciones, neurodegeneraciones). En este estado reactivo se convierten en 'nuevas células con nuevas funciones' pues cambian de manera importante sus funciones celulares con la expresión de nuevos genes. De esta forma pasan a ser actores principales en el escenario de las nuevas situaciones patológicas del Sistema Nervioso (SN). La activación de las células de neuroglia en principio es beneficiosa, tendente a solucionar los cambios patológicos, pero puede convertirse en perjudicial para el tejido nervioso. Asimismo, en los últimos años, se ha comprobado que también es causa de patología la falta de respuesta reactiva de las distintas células neuróglicas o la involución de estas células. Los estudios sobre estos diferentes tipos de células gliales reactivas han ampliado de manera muy importante los conocimientos que teníamos sobre la patogenia de las enfermedades del SN, y también nos están dando a conocer que pueden ser apoyos fundamentales para definir dianas farmacológicas terapéuticas o crear nuevas terapias celulares que ayuden a controlar el avance de las 'cascadas patogénicas' por la vía de activar la neuroprotección-neurorreparación y/o inhibir la neurotoxicidad-neurodegeneración

All members of the families of the neuroglia have the ability to adopt a reactive state ("gliosis" in general, "astrogliosis" "oligodendrogliosis" and "microgliosis" in its specific form) face to situations where importantly is modified homeostasis of the nervous tissue and / or normal functional dynamics of neurons and their accompanying neuroglial cells (trauma, neurotoxicity, infections, neurodegenerative processes). In this reactive state, neuroglial cells become 'new cells with new functions' because a significant change of their cellular functions occurs, mainly by the expression of new genes. Thus they become major players on the different stage of the new SN pathological situations. Activation of neuroglia cells is initially beneficial, aiming to solve the pathological changes, but it can turn detrimental to nerve tissue. Also, in recent years, it has been found that also the lack of reactive responses or the existence of "maladaptative responses" of the different neuroglial cells as well as the involution or regression of these cells, are important sources of nervous pathology. Studies of these different types of reactive glial cells have significantly expanded the knowledge we had about the pathogenesis of diseases of the SN. Moreover, many studies are revealing that they may be important to define new therapeutic drug targets or create new cell therapies to control the progress of the "pathogenic cascades", through activating neuroprotection-neurorepair and/or inhibiting the neurotoxicity-neurodegeneration

Brain local and regional neuroglial alterations in Alzheimer's Disease: cell types, responses and implications.

From birth to death, neurons are dynamically accompanied by neuroglial cells in a very close morphological and functional relationship. Three families have been classically considered within the CNS: astroglia, oligodendroglia and microglia. Many types/subtypes (including NGR2+ cells), with a wide variety of physiological and pathological effects on neurons, have been described using morphological and immunocytochemical criteria. Glio-glial, glio-neuronal and neuro-glial cell signaling and gliotransmission are phenomena that are essential to support brain functions. Morphofunctional changes resulting from the plasticity of all the glial cell types parallel the plastic neuronal changes that optimize the functionality of neuronal circuits. Moreover, neuroglia possesses the ability to adopt a reactive status (gliosis) in which, generally, new functions arise to improve and restore if needed the neural functionality. All these features make neuroglial cells elements of paramount importance when attempting to explain any physiological or pathological processes in the CNS, because they are involved in both, neuroprotection/neurorepair and neurodegeneration. There exist diverse and profound, regional and local, neuroglial changes in all involutive processes (physiological and pathological aging; neurodegenerative disorders, including Alzheimer ´s disease -AD-), but today, the exact meaning of such modifications (the modifications of the different neuroglial types, in time and place), is not well understood. In this review we consider the different neuroglial cells and their responses in order to understand the possible role they fulfill in pathogenesis, diagnosis and treatment (preventive or palliative) of AD. The existence of differentiated and/or concurrent pathogenic and neuro-protective/neuro-restorative astroglial and microglial responses is highlighted.

Blood-based biomarkers of Alzheimer's disease: diagnostic algorithms and new technologies.

New concepts about Alzheimer's disease (AD), considered as a clinical-biological entity, make essential the definition of biomarkers that could be used for the in vivo diagnosis of the disorder before dementia develops. Different types of genetic, biochemical and neuroimaging markers have been described, highlighting some of the changes that occur in the brain during the course of the disease, yet there is little proof of their pathognomonic and diagnostic value. Furthermore, many of the assays used are difficult to perform, the equipment/reagents are expensive or potentially hazardous (e.g.; use of radioactive compounds, CSF extraction). Thus, there is a need to define more suitable and convenient approaches, such as the determination of blood parameters that are easy to obtain and that can be repeated as necessary without contraindications. These data can be used by algorithms that combine specific and non-specific changes to classify patients at different stages of AD and/or distinguish AD from other related diseases with a greater specificity and reliability (> 80%). The blood parameters considered in this review are varied, including: ß-amyloid, tau, apolipoproteins and proteins, as well as the metabolic behavior of blood cells, etc. Among the proteins, cytokines/chemokines and other cell factors related to both neuro-inflammatory and peripheral-inflammatory processes in AD are of prime importance. New technologies to detect and quantify these substances, reasonably priced such as the vibrational spectroscopy, panels of parameters and algorithms to assess the results, would be fundamental for the early AD diagnosis and to define new potential therapies.

Vibrational spectroscopic analysis of peripheral blood plasma of patients with Alzheimer's disease.

Using Raman and infrared spectroscopy, we monitored spectral changes occurring in the blood plasma of patients with Alzheimer's disease (AD) in relation to healthy controls. The protein secondary structure as reflected by amide I band involves ß-sheet enrichment, which may be attributable to Aß peptide formation and to increasing proportion of the globulins that are ß-sheet rich. Likewise, the behavior of the infrared 1200-1000-cm(-1) region and the Raman 980-910- and 450-400-cm(-1) regions can be explained in terms of the said plasma composition change. Further, the 744-cm(-1) Raman band from healthy control plasma shows frequency upshifting in the course of AD, which may be generated by the platelets collected in blood plasma. Linear discrimination analysis and receiver operating characteristic (ROC) analysis have been used to distinguish between patients with AD and age-matched healthy controls with a diagnostic accuracy of about 94%.

Ultrastructural changes in the progress of natural Scrapie regardless fixation protocol.

Because few studies regarding ultrastructural pathological changes associated with natural prion diseases have been performed, the present study primarily intended to determine consistent lesions at the subcellular level and to demonstrate whether these changes are evident regardless of the fixation protocol. Thus far, no assessment method has been developed for classifying the possible variations according to the disease stage, although such an assessment would contribute to clarifying the pathogenesis of this neurodegenerative disease. Therefore, animals at different disease stages were included here. This study presents the first description of lesions associated with natural Scrapie in the cerebellum. Vacuolation, which preferentially occurs around Purkinje cells and which displays a close relation with glial cells, is one of the most novel observations provided in this study. The disruption of hypolemmal cisterns in this neuronal type and the presence of a primary cilium in the granular layer both represent the first findings concerning prion diseases. The possibility of including samples regardless of their fixation protocol is confirmed in this work. Therefore, a high proportion of tissue bank samples that are currently being wasted can be included in ultrastructural studies, which constitute a valuable source for information regarding physiological and pathological samples.

Astroglial cell subtypes in the cerebella of normal adults, elderly adults, and patients with Alzheimer's disease: a histological and immunohistochemical comparison.

Objectives and experimental design Cerebella of young adults, elderly adults, and patients with Alzheimer's disease (AD) (with and without cerebellar amyloid deposits) were studied by Golgi staining and glial fibrillary acid protein (GFAP) immunocytochemical methods. Observations Three subtypes of Golgi epithelial cells and nine subtypes of stellate neuroglia (both normal and hypertrophic) were defined by their morphology, their GFAP-reactivity, their specific location in the cortical layers, and their responses in senility and AD. The GFAP immunoreaction was subtype specific. In aged and AD cerebella, different morphological and GFAP-immunoreactive subtype-specific changes were observed: in the white matter, the subtypes were always GFAP-immunopositive, but in the grey matter some astroglial subtypes showed a variable or no increase in GFAP staining. The astrocytes at the limits of the granule cell layer showed more and longer processes. Variations were seen in one or more folia, involving one or more subtypes and affecting different numbers of cells of each subtype. No clear differences were seen in glial reactivity between beta-amyloid positive and ß-amyloid (Aß) negative AD cerebella. No important relationships were found between Aß deposits. In aged and AD cerebella, different subtypes expressed new proteins (APP, calretinin). Conclusions The existence of different glial subtypes in different locations suggests they have different functions. General and local variations in these subtypes suggest that both general and local induction factors must also exist. The responses of glial cells to as-yet undefined stimuli might lead to general or local neuronal changes important in senility and the pathogenic course of AD.

Envejecimiento cerebral normal y patológico: continuum fisiopatológico o dualidad de procesos involutivos / Normal and pathological brain aging: a physiopathological continuum or an involutive duality

Desde hace años existe una controversia sobre si existe una doble vía (dualidad involutiva) de involución senil del cerebro, que podemos denominar, respectivamente, hacia la senilidad fisiológica o «normal» sin signos de demencia, o bien hacia la senilidad "patológica" o Enfermedad de Alzheimer, que se manifiesta por la aparición de una demencia progresiva, o, por el contrario, una sola vía (continuum) que conduce desde los primeros signos de involución morfológica o funcional senil hasta la fase final de la demencia EA en todos los individuos. Además, en estos últimos años, se está produciendo una profunda revisión de los conceptos sobre la senilidad patológica / EA de manera que ya no se considera que dicho proceso de envejecimiento sólo existe tras efectuar un diagnóstico de demencia, sino que se inicia en el momento en que se produce una alteración de los circuitos cognitivos cerebrales y/o cambio neuropatológico. Con estos nuevos criterios se supone que la senilidad patológica / EA comprende diversas fases sin demencia (asintomáticas o prodrómicas) y otras con demencia de distinto grado. En esta revisión se analizan las razones que se aducen en defensa de una u otra teoría y las características morfofuncionales de los cerebros seniles normales y los patológicos. La mayoría de los estudios realizados apuntan que existen características diferenciales muy marcadas entre los cerebros seniles normales sin demencia y los patológicos con demencia, pero en otros existen grandes discrepancias entre la presencia o no demencia y la de signos de neuropatológicos. La existencia o no del continuum tiene también una muy importante repercusión práctica pues tanto la prevención como la asistencia de las personas mayores dependerán del posible número de individuos afectados: bien solamente los individuos de riesgo o bien toda la población. Existen algunos terrenos donde la investigación podría hacer avanzar nuestros conocimientos en el envejecimiento cerebral, especialmente en el estudio pormenorizado de los individuos controles sanos de entre 30 y 60 años, en el de los "centenarios" con y sin demencia y en grupos con características diferenciales neuropsicológicas (posibles estadíos intermedios de EA según el nuevo "lexicón"). También sería de gran interés estudiar comparativamente el envejecimiento cerebral humano con el de otras especies de mamíferos que no presentaran patología amiloide o tau y con los primates que pueden presentar patología amiloidea. En este último sentido, los animales transgénicos con patología inducida amiloide o/y tau también serían importantes fuentes de información

For years, there is a controversy whether there is a two-way (involutive duality) of senile involution of the brain, which may be called, respectively, pathway to the physiological or "normal" senility, without signs of dementia but with neuronal adaptative responses, and pathway to "pathological" senility or Alzheimer's Disease (AD), which is characterized by the appearance of a progressive dementia, or, conversely, a single way (continuum) leading from the first morphological or functional signs of senile involution until the final stage of AD dementia in all individuals. Moreover, in recent years, a thorough review of the concepts of the pathological senility / EA is producing, so that is not now considered necessary to have dementia to diagnose a pathological aging process because it is considered that the pathological aging / EA is started at the time that a disturbance in cognitive brain circuits and / or neuropathological changes occurs. With these new criteria different clinic-pathological stages are supposed from normal senility to terminal pathological senility / EA, without dementia (prodromal or asymptomatic) and with varying degrees of dementia. In this review the reasons given in defense of one or another theory are analyzed, as well as the morphofunctional features of normal and pathological senile brains. Most studies indicate that there are very marked differential characteristics between normal brains without dementia and senile pathological brains with dementia, but in other, large discrepancies exist between the presence or absence of dementia and the existence or not of neuropathological signs. The existence or not of the continuum also has a very important practical implication for both prevention and care of the elderly, because the possible number of individuals affected: the entire population or only at-risk individuals in the pathological brain senility pathway. There are some areas where research could improve our knowledge on brain aging, especially in the detailed study of healthy control subjects between 30 and 60, «centenarians» with and without dementia and individuals with neuropsychological characteristics different to AD (possible intermediate stages of AD according to the new «lexicon»). It would also be of great interest a comparative study of human brain aging with that of other mammalian species that showed no amyloid or tau pathology and primates that may have amyloid pathology. Transgenic animals with induced amyloid and /or tau pathology, are also important sources of information on pathological aging

Morphological approach to assess the involvement of astrocytes in prion propagation.

Transmissible Spongiform Encephalopathies (TSEs) are a group of neurodegenerative disorders affecting animals and humans and for which no effective treatment is available to date. Vacuolation, neuronal/neurite degeneration, deposition of pathological prion protein (PrPsc) and gliosis are changes typically found in brains from TSE affected individuals. However, the actual role of this last feature, microgliosis and astrocytosis, has not been precisely determined. The overall objective of this work is to assess the involvement of glial cells as components of the host protective system in prion propagation; specifically, to analyze the behavior of astroglial cells in prion progression. To achieve this aim, histopathological and immunohistochemical techniques were carried out on samples from cerebella using Scrapie as the prototype of natural TSEs as this made it possible to assess different stages of the disease; specifically, ages and genotypes from Scrapie-affected animals corresponding to different sources, by using optical, confocal and electron microscopy. The results provided in the present study demonstrate the indisputable involvement of astroglia in prion progression by showing specific changes of this glial population matching up to the evolution of the disease. Moreover, cerebellar lesions mainly associated to Purkinje cells that have not previously been reported in animal prion diseases in natural transmission are described here. The close relationship between PrPsc and GFAP hiperimmunoreactivity and Purkinje cells, alongside the evident thickening of their neurites at terminal stages demonstrated in this study, suggest that these neurons are the main target of this neurodegenerative disease.

Variability in the effects of nicotine on different regions of the brain: changes in the concentration of superoxide dismutase isoforms.

Previous studies have shown that rats subjected to subchronic treatment with nicotine experience changes in COX-2 (a marker of pro-inflammatory systems) and accumulate lipid hydroperoxides (a marker of oxidative stress) in the CNS (CNSMC, 2010; 10:180-206) (hippocampus, frontoparietal cortex and cerebellar cortex). Such changes are specific to each region since each contains different types of neuronal and glial cells with different nicotine receptors. They also differ in animals exposed to a source of oxidative stress, such as D-amphetamine. This paper discusses the changes in other markers of oxidative stress - the isozymes of superoxide dismutase Mn-SOD and Cu/Zn-SOD - in nicotine- and nicotine + D-amphetamine-treated rats. The biochemical and histochemical changes observed were specific to each region (in general very marked in the frontoparietal cortex and the hippocampus but less so in the cerebellar cortex) and each type of neuronal and glial cell. The SODs induced by nicotine may exert a neuroprotective effect via the reduction of oxidative stress. This might be beneficial in the treatment of neurodegenerative diseases. The fact that nicotine did not greatly increase the SODs in the rats treated with D-amphetamine may indicate that the effect of nicotine is partially or totally abolished in situations of oxidative stress. However, since ROS and lipid hydroperoxide levels are also reduced when nicotine is administered to such animals, it could be argued that nicotine is beneficial.

Discrimination analysis of blood plasma associated with Alzheimer's disease using vibrational spectroscopy.

In this study we have determined whether Raman and infrared spectroscopy of blood plasma differentiates Alzheimer's disease (AD) from normal aging of healthy controls. Spectroscopic analysis was conducted on blood plasma samples from 8 mild AD, 16 moderate AD, 11 severe AD, and 12 normal elderly control persons using Fourier transform spectrometers and a near-infrared laser beam as excitation source for Raman spectroscopy. Spectra were processed employing discriminant analysis to determine whether band areas and frequency-intensity relationships might reveal biochemical differences associated with AD. Seven spectral biomarkers were identified in the Raman regions of 1700-1600 cm-1 (protein secondary structure), 980-910 cm-1 (protein α-helices), 790-730 cm-1 (protein tertiary structure), and 440-390 cm-1 (protein backbone) and in the infrared regions of 1700-1600 cm-1 (protein secondary structure) and 1150-1000 cm-1 (oxidative stress). This discriminant analysis model differentiated AD from normal aging of elderly control persons with a sensitivity of 89% and specificity of 92%. Moreover, specificity increases to 100% for the detection of mild AD. In summary, our results open the possibility of using this spectroscopic approach as a non-invasive, rapid, and relatively inexpensive procedure for early accurate diagnosis of AD.

Estudio objetivo del olfato mediante resonancia magnética funcional / Objective assessment of olfactory function using functional magnetic resonance imaging

Objetivo: Mostrar los resultados del olfatómetro capaz de generar tareas olfativas en un equipo de resonancia magnética funcional (fMRI). Material y métodos: Estudiamos 10 sujetos normales: 5 varones y 5 mujeres. El olfatómetro está diseñado para que el estímulo que produce se sincronice con el equipo de fMRI mediante la señal desencadenante que suministra el propio equipo. El olfatómetro es capaz de: seleccionar el olor, secuenciar los distintos olores, programar la frecuencia y duración de los olores y controlar la intensidad del olor. El paradigma utilizado responde a un diseño de activación asociada a eventos, en el que la duración del bloque de activación y de reposo es de 15s. La duración del estímulo olfativo (butanol, menta o café) es de 2 segundos, durante toda la serie que consta de 9 ciclos. Resultados: Se ha observado reactividad (contraste BOLD) en las diferentes áreas cerebrales involucradas en las tareas olfativas: bulbo olfatorio, córtex entorrinal (4%), amigdala (2,5%) y córtex temporoparietal. Las áreas relacionadas con integración de las emociones tienen una reactividad mayor. Conclusiones: El dispositivo propuesto nos permite controlar de forma automática y sincronizada los olores necesarios para estudiar la actividad de las áreas olfatorias cerebrales mediante fMRI(AU)

Objective: To show the results of a device that generates automated olfactory stimuli suitable for functional magnetic resonance imaging (fMRI) experiments. Material and methods: Ten normal volunteers, 5 women and 5 men, were studied. The system allows the programming of several sequences, providing the capability to synchronise the onset of odour presentation with acquisition by a trigger signal of the MRI scanner. The olfactometer is a device that allows selection of the odour, the event paradigm, the time of stimuli and the odour concentration. The paradigm used during fMRI scanning consisted of 15-s blocks. The odorant event took 2s with butanol, mint and coffee. Results: We observed olfactory activity in the olfactory bulb, entorhinal cortex (4%), amygdala (2.5%) and temporo-parietal cortex, especially in the areas related to emotional integration. Conclusions: The device has demonstrated its effectiveness in stimulating olfactory areas and its capacity to adapt to fMRI equipment(AU)

Objective assessment of olfactory function using functional magnetic resonance imaging.

OBJECTIVE: To show the results of a device that generates automated olfactory stimuli suitable for functional magnetic resonance imaging (fMRI) experiments. MATERIAL AND METHODS: Ten normal volunteers, 5 women and 5 men, were studied. The system allows the programming of several sequences, providing the capability to synchronise the onset of odour presentation with acquisition by a trigger signal of the MRI scanner. The olfactometer is a device that allows selection of the odour, the event paradigm, the time of stimuli and the odour concentration. The paradigm used during fMRI scanning consisted of 15-s blocks. The odorant event took 2s with butanol, mint and coffee. RESULTS: We observed olfactory activity in the olfactory bulb, entorhinal cortex (4%), amygdala (2.5%) and temporo-parietal cortex, especially in the areas related to emotional integration. CONCLUSIONS: The device has demonstrated its effectiveness in stimulating olfactory areas and its capacity to adapt to fMRI equipment.

Infrared spectroscopic analysis of mononuclear leukocytes in peripheral blood from Alzheimer's disease patients.

Peripheral mononuclear leukocytes from Alzheimer's disease (AD) patients were analyzed by infrared spectroscopy and their spectroscopic properties were compared with those from age-matched healthy controls. Two-dimensional correlation analysis of mean spectra measured at various disease stages shows that the protein secondary structure from AD patients involves ß-sheet enrichment and carbonyl intensity increase relative to healthy controls. The area percentages of ß-sheets, which were obtained by using a peak ratio second-derivative spectral treatment, were used for receiver operating characteristic (ROC) analysis to distinguish between patients with AD and age-matched healthy controls. The critical concentration and area under the curve (AUC) were determined by this curve analysis which showed a good performance for this quantitative assay. The results were 90% sensitivity and 90.5% specificity for determinations involving mild and moderate AD patients, and 82.1% sensitivity and 90.5% specificity for determinations involving patients at the three AD stages (mild, moderate, and severe). The AUC was greater than 0.85 in both scenarios. Taken together these results show that healthy controls are distinguished from mild and moderate AD patients better than from patients with severe disease and suggest that this infrared analysis is a promising strategy for AD diagnostics.